FLGT Fulgent Genetics Inc

Price (delayed)

$73.55

Market cap

$2.13B

P/E Ratio

4.47

Dividend/share

N/A

EPS

$16.46

Enterprise value

$2B

Highlights
The net income has soared by 95% from the previous quarter
The price to earnings (P/E) is 89% lower than the last 4 quarters average of 38.3
FLGT's quick ratio is down by 45% year-on-year and by 14% since the previous quarter

Key stats

What are the main financial stats of FLGT
Market
Shares outstanding
29.01M
Market cap
$2.13B
Enterprise value
$2B
Valuations
Price to earnings (P/E)
4.47
Price to book (P/B)
2.65
Price to sales (P/S)
2.74
EV/EBIT
3.59
EV/EBITDA
3.56
EV/Sales
2.58
Earnings
Revenue
$773.39M
EBIT
$555.97M
EBITDA
$560.67M
Free cash flow
$325.26M
Per share
EPS
$16.46
Free cash flow per share
$11.28
Book value per share
$27.76
Revenue per share
$26.82
TBVPS
$34.65
Balance sheet
Total assets
$999.08M
Total liabilities
$197.52M
Debt
$15.05M
Equity
$801.57M
Working capital
$462.61M
Liquidity
Debt to equity
0.02
Current ratio
3.35
Quick ratio
3.19
Net debt/EBITDA
-0.24
Margins
EBITDA margin
72.5%
Gross margin
79.3%
Net margin
53.9%
Operating margin
72.3%
Efficiency
Return on assets
81.6%
Return on equity
101.4%
Return on invested capital
159.6%
Return on capital employed
69.3%
Return on sales
71.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FLGT stock price

How has the Fulgent Genetics stock price performed over time
Intraday
1.7%
1 week
-12.44%
1 month
4.56%
1 year
345.76%
YTD
41.17%
QTD
-23.88%

Financial performance

How have Fulgent Genetics's revenue and profit performed over time
Revenue
$773.39M
Gross profit
$613.56M
Operating income
$558.99M
Net income
$416.96M
Gross margin
79.3%
Net margin
53.9%
The net income has soared by 95% from the previous quarter
Fulgent Genetics's operating income has soared by 93% from the previous quarter
The gross profit has soared by 85% from the previous quarter
Fulgent Genetics's revenue has surged by 83% QoQ

Growth

What is Fulgent Genetics's growth rate over time

Valuation

What is Fulgent Genetics stock price valuation
P/E
4.47
P/B
2.65
P/S
2.74
EV/EBIT
3.59
EV/EBITDA
3.56
EV/Sales
2.58
The price to earnings (P/E) is 89% lower than the last 4 quarters average of 38.3
FLGT's EPS has soared by 74% since the previous quarter
The company's equity rose by 41% QoQ
The price to book (P/B) is 28% lower than the last 4 quarters average of 3.6 and 10% lower than the 5-year quarterly average of 2.9
Fulgent Genetics's revenue has surged by 83% QoQ
FLGT's P/S is 51% below its 5-year quarterly average of 5.5 and 48% below its last 4 quarters average of 5.2

Efficiency

How efficient is Fulgent Genetics business performance
The company's return on invested capital rose by 12% QoQ
The return on equity has grown by 9% since the previous quarter
The company's return on assets rose by 8% QoQ
FLGT's ROS is up by 6% since the previous quarter

Dividends

What is FLGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLGT.

Financial health

How did Fulgent Genetics financials performed over time
Fulgent Genetics's total liabilities has soared by 51% from the previous quarter
FLGT's current ratio is down by 47% year-on-year and by 17% since the previous quarter
Fulgent Genetics's debt is 98% less than its equity
The company's equity rose by 41% QoQ
FLGT's debt to equity is down by 33% since the previous quarter and by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.